Announcement of the DOVACC phase II trial

Ultimovacs Announces Phase II DOVACC Collaboration Study in Ovarian Cancer with the Nordic Society of Gynaecological Oncology – Clinical Trial Unit, the European Network of Gynaecological Oncological Trial Groups and AstraZeneca. Read the full announcement below.

Ultimovacs management hosted a webcast on monday 11. January at 11:00 discussing the DOVACC clinical trial in more detail. The webcast can be accessed here, and is also available in the “Investors/Reports and Presentations”-section.